FDA approves new daily pill for certain advanced breast cancers

The FDA approved Etcamah (camizestrant), a new daily pill for certain advanced breast cancers with ESR1 mutations. A blood test can detect treatment resistance before scans show progression, allowing earlier treatment changes. Clinical trial results showed longer progression-free survival, although additional studies are needed to confirm long-term patient benefits.